Search Results

Korean Hospital Team Develops AI Model to Improve Bone Metastasis Detection Using PET/CT and Other Information

A research team at Seoul Metropolitan Government Seoul National University Boramae Medical Center has recently developed an artificial intelligence model capable of identifying bone metastases that are difficult to detect on CT images. By incorporating MRI and PET/CT information during the training process, the model enables lesions that are inconspicuous on CT and prone to being missed to be included in the training data, thereby enhancing detection capability. Bone metastasis is an important basis for determining cancer staging and formulating treatment plans. If lesions are not clearly visible on CT images, bone metastasis may be detected late and may lead to complications such as pathological fractures and spinal cord compression. Previous related AI studies have largely relied on lesions clearly visible on CT to build training data, and the research team believes that this approach may...

2026-08-17

Oak Ridge National Laboratory marks 80 years of isotope research and production, with applications spanning medicine, industry, and scientific research

On August 2, 1946, the Clinton Laboratories in Oak Ridge, Tennessee, held the first formal ceremony to deliver reactor-produced radioactive isotopes. A shipment of carbon-14 was sent from there to the Barnard Free Skin and Cancer Hospital in St. Louis, Missouri. Over the past 80 years, this event has been regarded as the starting point of Oak Ridge National Laboratory's isotope research and production endeavors, and also marked the beginning of broader civilian applications for reactor-produced radioactive isotopes. After World War II, the U.S. scientific community began exploring peaceful uses of atomic energy, with radioactive isotopes becoming an important direction. As unstable variants of elements, radioactive isotopes release radiation during decay and can be used...

2026-08-15

NRC to Hold Online Public Meeting on Proposed Medical Use Licensing Rule

The U.S. Nuclear Regulatory Commission recently announced it will hold an online public meeting from 1:00 p.m. to 2:30 p.m. Eastern Time on August 20 to introduce the proposed rule aimed at reducing barriers to medical use licensing. The proposed rule was published in the Federal Register on July 27. During the meeting, NRC staff will outline the key provisions of the rule and related implementation activities, and answer questions from the public. The meeting is open to the public and will focus on regulatory processes related to medical use licensing, with the goal of explaining and discussing the proposed rule and subsequent implementation arrangements...

2026-08-16

FDA Approves Tauklarify, a Tau PET Imaging Agent for Alzheimer's Disease

The U.S. Food and Drug Administration has approved Tauklarify, a new brain imaging agent for the evaluation of Alzheimer's disease. The drug, also known as MK-6240, is a radioactive diagnostic agent for positron emission tomography (PET) in adults, primarily indicated for adults with cognitive impairment who require physician assessment of abnormal tau protein accumulation in the brain. The twisted, insoluble fibrous deposits formed by tau protein are believed to be associated with neurodegenerative diseases such as Alzheimer's disease. The developer, Lantheus, stated that the safety of Tauklarify was evaluated in two clinical trials involving more than 1,700 subjects. Adverse reactions...

2026-08-16

CGN Medical and West China Hospital of Sichuan University Sign Proton Therapy Innovation Technology Cooperation Agreement

On August 14, the 32nd China International Medical Instruments and Equipment Exhibition & Technology Exchange Conference (China-Hospeq 2026) opened at the China National Convention Center in Beijing. CGN Medical was invited to exhibit under the theme of "Precision Radiotherapy · Nuclear Medicine Empowerment," showcasing achievements in the healthcare sector including the Hezhi® proton therapy system and the Hejia® germanium-gallium generator. The exhibits covered radiotherapy solutions, new medical isotopes, SiPM chips for molecular imaging, radiation protection, and medical device sterilization. On the first day of the exhibition, representatives from relevant departments and institutions visited the CGN Medical booth, learning about CGN's product layout and technological progress in the nuclear medicine field, and showing interest in its efforts in the domestic substitution of high-end medical equipment...

2026-08-15

ASP Isotopes Plans Commercial Delivery of Multiple Stable Isotopes in Second Half of 2026

ASP Isotopes Inc. recently presented its expansion plans for isotope production, radiopharmaceuticals, and helium operations at Canaccord Genuity's 46th Annual Growth Conference. The company aims to begin commercial delivery of stable isotopes including silicon-28, carbon-14, and ytterbium-176 in the second half of 2026. Victor Petkov, the company's Chief Commercial Officer, stated that ASP Isotopes is leveraging its proprietary enrichment technology to serve electronics, nuclear medicine, and nuclear fuel-related markets. Currently, the company operates three production facilities in Pretoria, South Africa, primarily producing silicon-28 for semiconductor applications, as well as carbon-14 and ytterbium-176 for nuclear medicine-related uses. Regarding isotope supply...

2026-08-13

Maistop Completes Pre-A Round Financing to Advance Medical Radionuclide Industrialization via Electron Accelerator Method

August 12 news, Xi'an Maistop Technology Co., Ltd. recently completed its Pre-A round of financing, with investors including the Central Enterprise Strategic Emerging Fund and Guoxin Venture Capital Fund, both under China Reform Holdings Corporation. The proceeds from this round will primarily be used for site construction, equipment procurement, technology R&D, and daily operations. Founded in 2019, Maistop is a technology enterprise engaged in the R&D and production of medical radionuclides as well as nuclear medicine technical services. The company focuses on the preparation of medical radionuclides via the electron accelerator photonuclear reaction method, with core products including Actinium-225, Lead-212, Copper-67, and Molybdenum-99. Among these, Actinium-225 is a scarce radionuclide of significant interest in alpha-emitting nuclide targeted therapy, with relatively strong global clinical demand...

2026-08-13

Southwest University of Science and Technology Releases Medical Radioactive Waste Treatment Technology Covering Liquid, Gas, and Solid Waste Management

On August 10, the Mianyang Science and Technology City Strategic Development Research Center held an online innovation achievement release conference, unveiling a medical radioactive waste treatment technology developed by the School of National Defense Science and Technology / School of Nuclear Science and Technology at Southwest University of Science and Technology. The technology targets radioactive contaminants including liquid waste, off-gas, and solid waste generated during nuclear medicine diagnosis and treatment, offering a full-chain comprehensive treatment solution. The conference attracted 87,000 experts in the nuclear medicine field, departmental representatives, and enterprise users. With the rapid development of the domestic nuclear medicine industry, insufficient radioactive waste disposal capacity has gradually become a key issue facing the industry's safe expansion. Relevant data show that over 96% of nuclear medicine departments nationwide are constrained by decay tank capacity...

2026-08-13

American Society for Radiation Oncology Foundation to Award $2.4 Million in Grants to 14 Researchers

The American Society for Radiation Oncology (ASTRO) Foundation will award a total of $2.4 million in research grants to 14 scientists dedicated to advancing patient care in radiation medicine. ASTRO stated that the 2026 awards are the first annual grants issued since the society renamed its foundation to LightSpeed—ASTRO Foundation earlier this year. The rebranded foundation will focus on accelerating relevant research and strengthening workforce development in the field of radiation oncology. This round of funding is co-sponsored by the American Cancer Society, the American Association of Physicists in Medicine, the Breast Cancer Research Foundation, the LUNGevity Foundation, and the Prostate Cancer Foundation. ASTRO CEO Vive...

2026-08-13

CGN Hezhi® Proton Therapy System Clinical Performance Successfully Passes Expert Review

On July 31, the expert review meeting for the clinical performance evaluation of the CGN Hezhi® Proton Therapy System was held at the CGN Proton Therapy Equipment Manufacturing Base. Clinical experts from Sun Yat-sen University Cancer Center, National Cancer Center/Cancer Hospital of Chinese Academy of Medical Sciences, Sichuan Cancer Hospital, National Cancer Center/Cancer Hospital of Chinese Academy of Medical Sciences Shenzhen Hospital, and Shandong First Medical University Affiliated Cancer Hospital attended the review meeting.▲Expert review of CGN Hezhi® Proton Therapy System clinical performanceAt the review meeting, the relevant person in charge of CGN Medical Technology Co., Ltd. (hereinafter referred to as the "Company") introduced that the comprehensive verification platform for the proton therapy system has achieved full-process independent controllability from design, procurement, production,...

2026-08-12

China's First Qualification for Radiation Health Testing and Evaluation of BNCT Equipment Approved

Recently, the Beijing Municipal Health Commission, in accordance with the "Administrative Measures for Radiation Health Technical Service Institutions" (Guoweiban ZhiJian Fa [2026] No. 1), organized experts to conduct on-site reviews of two qualification expansion applications submitted by the National Center for Occupational Safety and Health under the National Health Commission. The projects include performance testing and evaluation of Boron Neutron Capture Therapy (BNCT) equipment and thyroid iodine-131 testing. During the review process, the expert panel conducted a comprehensive examination of the center's management system, personnel allocation, instruments and equipment, and technical capabilities related to radiation health testing and evaluation through document review, technical inquiries, on-site practical operations, and simulated demonstrations...

2026-08-12

Australia's OPAL Multipurpose Reactor Marks 20 Years of Operation: Supporting Nuclear Medicine, Industrial Silicon Irradiation, and Neutron Science

The OPAL multipurpose reactor at the Lucas Heights campus of the Australian Nuclear Science and Technology Organisation (ANSTO), located south of Sydney, has marked the 20th anniversary of achieving first criticality. On August 12, 2006, OPAL achieved a self-sustaining controlled nuclear chain reaction, marking the facility's transition from the construction phase to the scientific operations phase. ANSTO stated that over the past 20 years, OPAL has become one of Australia's key nuclear science infrastructures, serving multiple fields including medicine, industry, and scientific research. OPAL is not a power reactor and is not used for electricity generation. According to available information, Australian federal law and relevant state and territory legislation prohibit the construction of nuclear power reactors, fuel fabrication, and waste disposal facilities. Unlike power reactors used for...

2026-08-12

Leshan Accelerates Construction of Medical Isotope Production Base to Promote Domestic Substitution of "Anti-Cancer Nuclear Drugs"

On August 11, at the Leshan special press conference of "Myriad Scenes in Sichuan · Embarking on the '15th Five-Year Plan'", Leshan Mayor Zhao Yingchun stated that Leshan is accelerating the construction of the largest and most comprehensive medical isotope production base in China. Upon completion, the project will help break the foreign monopoly and import dependence on related products, promote the domestic substitution of anti-cancer nuclear drugs, and enable more patients to access domestically produced drugs with lower prices and better efficacy. Zhao Yingchun noted that during the "14th Five-Year Plan" period, Leshan has focused on building the "China Green Silicon Valley", a world-class tourist destination, and a major regional transportation and logistics hub in the province, continuously promoting high-quality development, with its economic output surpassing 250 billion yuan...

2026-08-12

University of Tokyo and University of York Successfully Validate Positronium Ratio Imaging Principle for the First Time

A research team from the Graduate School of Engineering at the University of Tokyo and the University of York in the UK established a novel geometric imaging principle utilizing positron three-photon decay. Using a gamma-ray measurement system comprising scintillators and silicon photomultipliers (SiPMs), along with the existing PET radiopharmaceutical ^18F-FDG, they successfully visualized the positronium three-photon decay ratio for the first time, completing the proof-of-principle for Positronium Ratio Imaging (PRI). The findings were published in *Communications Physics*. Current clinical nuclear medicine PET examinations primarily utilize gamma rays generated from two-photon annihilation between positrons and electrons to visualize drug accumulation in the body. While this method provides quantitative information on metabolism or drug uptake, it offers limited insight into microenvironmental features such as tissue hypoxia, which are closely related to disease malignancy. In recent years, researchers have attempted to obtain additional tissue information through the average lifetime of positronium formed during positron annihilation, but this approach typically requires the introduction of special nuclides or agents, limiting its practical application.

2026-08-12

LG Electronics Launches FDA-Approved 40-Inch Diagnostic Monitor for B2B Medical Imaging Market

LG Electronics announced on August 12 that it has launched a new 40-inch diagnostic monitor, the 40HT513D, targeting the business-to-business (B2B) medical display market. The product has received approval from the U.S. Food and Drug Administration (FDA) and is primarily intended for medical image interpretation. According to the company, the 40HT513D features a curved IPS black panel with a 21:9 aspect ratio and a resolution of 5120×2160, delivering approximately 11 million pixels. LG Electronics stated that this design consolidates image reading tasks that previously required three 3-megapixel monitors into a single screen. Physicians can simultaneously view and compare current and historical images from X-ray, CT scans, and MRI scans on the same display...

2026-08-12